Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Change in Cash (2016 - 2025)

Sangamo Therapeutics has reported Change in Cash over the past 16 years, most recently at -$9.6 million for Q4 2025.

  • Quarterly results put Change in Cash at -$9.6 million for Q4 2025, down 452.59% from a year ago — trailing twelve months through Dec 2025 was -$22.5 million (down 583.81% YoY), and the annual figure for FY2025 was -$22.5 million, down 583.81%.
  • Change in Cash for Q4 2025 was -$9.6 million at Sangamo Therapeutics, down from -$9.3 million in the prior quarter.
  • Over the last five years, Change in Cash for SGMO hit a ceiling of $46.9 million in Q2 2021 and a floor of -$58.6 million in Q1 2022.
  • Median Change in Cash over the past 5 years was -$8.8 million (2021), compared with a mean of -$5.6 million.
  • Biggest five-year swings in Change in Cash: crashed 601.64% in 2022 and later soared 225.19% in 2024.
  • Sangamo Therapeutics' Change in Cash stood at $1.9 million in 2021, then soared by 206.26% to $5.9 million in 2022, then crashed by 292.54% to -$11.3 million in 2023, then skyrocketed by 124.02% to $2.7 million in 2024, then tumbled by 452.59% to -$9.6 million in 2025.
  • The last three reported values for Change in Cash were -$9.6 million (Q4 2025), -$9.3 million (Q3 2025), and $13.2 million (Q2 2025) per Business Quant data.